Insider Selling: GoodRx (NASDAQ:GDRX) Major Shareholder Sells $1,574,351.68 in Stock

GoodRx Holdings, Inc. (NASDAQ:GDRX) major shareholder Francisco Partners Iv, L.P. sold 447,259 shares of the stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $3.52, for a total value of $1,574,351.68. Following the sale, the insider owned 913,592 shares in the company, valued at $3,215,843.84. The trade was a 32.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Francisco Partners Iv, L.P. also recently made the following trade(s):

• On Friday, August 21st, Francisco Partners Iv, L.P. sold 274,717 shares of GoodRx stock. The stock was sold at an average price of $3.50, for a total value of $961,509.50.
• On Wednesday, August 19th, Francisco Partners Iv, L.P. sold 471,975 shares of GoodRx stock. The shares were sold at an average price of $3.53, for a total value of $1,666,071.75.

GoodRx Stock Performance

GDRX traded down $0.11 during trading on Friday, reaching $3.45. 1,746,243 shares of the company were exchanged, compared to its average volume of 1,833,117. The stock has a market cap of $1.18 billion, a P/E ratio of 86.27, a PEG ratio of 1.77 and a beta of 1.60. The firm has a 50 day moving average of $3.13 and a 200 day moving average of $2.63. The company has a current ratio of 1.38, a quick ratio of 1.38 and a debt-to-equity ratio of 0.74. GoodRx Holdings, Inc. has a 52 week low of $1.77 and a 52 week high of $5.81.

GoodRx (NASDAQ:GDRX) last issued its earnings results on Wednesday, August 5th. The company reported $0.08 earnings per share for the quarter, hitting the consensus estimate of $0.08. The firm had revenue of $200.41 million for the quarter, compared to analyst estimates of $193.23 million. GoodRx had a return on equity of 7.22% and a net margin of 2.07%.The firm’s revenue for the quarter was down 1.3% on a year-over-year basis. During the same period last year, the company earned $0.09 earnings per share. On average, sell-side analysts forecast that GoodRx Holdings, Inc. will post 0.16 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on GDRX. Citigroup increased their price objective on shares of GoodRx from $4.00 to $5.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Leerink Partners set a $5.00 target price on shares of GoodRx in a research note on Thursday, August 6th. UBS Group upped their target price on shares of GoodRx from $2.50 to $3.75 and gave the stock a “neutral” rating in a research report on Thursday, August 13th. The Goldman Sachs Group restated a “neutral” rating and issued a $4.00 price target on shares of GoodRx in a research note on Friday, August 7th. Finally, Weiss Ratings raised GoodRx from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, August 7th. Four investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat.com, GoodRx has a consensus rating of “Hold” and an average target price of $4.23.

Institutional Investors Weigh In On GoodRx

Several institutional investors have recently bought and sold shares of the stock. Headlands Technologies LLC bought a new position in GoodRx in the 2nd quarter valued at about $30,000. Technology Crossover Management X Ltd. acquired a new position in shares of GoodRx during the second quarter valued at approximately $4,762,000. Bank of New York Mellon Corp bought a new stake in GoodRx during the second quarter worth approximately $540,000. Essential Partners LLC raised its holdings in GoodRx by 375.4% during the first quarter. Essential Partners LLC now owns 14,304 shares of the company’s stock worth $28,000 after purchasing an additional 11,295 shares in the last quarter. Finally, Amundi acquired a new stake in GoodRx in the first quarter worth approximately $37,000. Institutional investors and hedge funds own 63.77% of the company’s stock.

GoodRx Company Profile

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.